N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population

References

• Agúndez JA, García-Martín E. 2018. Human arylamine N-acetyltransferase type 2: phenotypic correlation with genotype-A clinical perspective. In Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics (pp. 69–89). Singapore: SG World Scientific Publishing Company.
   Google Scholar
• Agúndez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benítez J. 1996. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics. 6(6):501–512.
   PubMedGoogle Scholar
• Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA. 1996. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 276(18):1494–1501.
   PubMed Web of Science ®Google Scholar
• Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, Winkler L, Oesch F. 1996. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathioneS-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem. 236(1):184–186.
   PubMed Web of Science ®Google Scholar
• Araujo OC, de Paula VS, do Ó, KM, Villela-Nogueira CA, Araujo NM. 2021. Association of polymorphisms in the glutathione S-transferase theta-1 gene with cirrhosis and hepatocellular carcinoma in Brazilian patients with chronic hepatitis C. Vaccines. 9(8):831.
   Web of Science ®Google Scholar
• Asim M, Khan LA, Husain SA, Husain S, Sarma MP, Ahmad I, Sharma JK, Sharma A, Sharma S, Thayumanavan L. 2010. Genetic polymorphism of glutathione S transferases M1 and T1 in Indian patients with hepatocellular carcinoma. Dis Markers. 28(6):369–376.
   PubMed Web of Science ®Google Scholar
• Autrup H. 2000. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res Genet Toxicol Environ Mutagen. 464(1):65–76.
   Web of Science ®Google Scholar
• Avirmed S, Khuanbai Y, Sanjaajamts A, Selenge B, Dagvadorj BU, Ohashi M. 2021. Modifying effect of smoking on GSTM1 and NAT2 in relation to the risk of bladder cancer in mongolian population: a case-control study. Asian Pac J Cancer Prev. 22(8):2479–2485.
   PubMedGoogle Scholar
• Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. 1993. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 14(8):1689–1692.
   PubMed Web of Science ®Google Scholar
• Boccia S, Miele L, Panic N, Turati F, Arzani D, Cefalo C, Amore R, Bulajic M, Pompili M, Rapaccini G. 2015. The effect of CYP, GST, and SULT polymorphisms and their interaction with smoking on the risk of hepatocellular carcinoma. Biomed Res Int. 2015:179867.
   PubMed Web of Science ®Google Scholar
• Chang-Claude J, Kropp S, Jäger B, Bartsch H, Risch A. 2002. Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Prev Biomark. 11(8):698–704.
   PubMed Web of Science ®Google Scholar
• Da Silva TD, Felipe AV, de Lima JM, Oshima CTF, Forones NM. 2011. N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer. World J Gastroenterol. 17(6):760–765.
   PubMed Web of Science ®Google Scholar
• Long X, Ma Y, Wei Y, Deng Z. 2006. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res. 36(1):48–55.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, et al.. 2020. A concise review on the frequency, major risk factors and surveillance of hepatocellular carcinoma (HCC) in β-thalassemias: past, present and future perspectives and the ICET-A experience. Mediterr J Hematol Infect Dis. 12:e2020006.
   PubMed Web of Science ®Google Scholar
• Farker K, Schotte U, Scheele J, Hoffmann A. 2003. Impact of N-acetyltransferase polymorphism (NAT2) in hepatocellular carcinoma (HCC) –an investigation in a department of surgical medicine. Exp Toxicol Pathol. 54(5–6):387–391.
   PubMedGoogle Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 127(5 Suppl 1):S35–S50.
   PubMed Web of Science ®Google Scholar
• Ferreira GD, Fernandes GMM, Penteado C, Cória VR, Galbiatti-Dias ALDS, Russo A, Castanhole-Nunes MMU, Silva RFD, Silva RCMAD, Pavarino ÉC. 2021. Polymorphisms in xenobiotic metabolism-related genes in patients with hepatocellular carcinoma: a case-control study. Xenobiotica. 51(6):737–744.
   PubMed Web of Science ®Google Scholar
• Gelatti U, Covolo L, Talamini R, Tagger A, Barbone F, Martelli C, Cremaschini F, Franceschi S, Ribero ML, Garte S. 2005. N‐Acetyltransferase‐2, glutathione S‐transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case‐control study. Int J Cancer. 115(2):301–306.
   PubMed Web of Science ®Google Scholar
• Guaoua S, Ratbi I, Laarabi FZ, Elalaoui SC, Jaouad IC, Barkat A, Sefiani A. 2014. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genet. 15(1):1–6.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Flanagan JU, Jowsey IR. 2005. Glutathione transferases. Annu Rev Pharmacol Toxicol. 45:51–88.
   PubMed Web of Science ®Google Scholar
• Hirvonen A. 1999. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect. 107(suppl 1):37–47.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Beaty TH, Liang KY, Coresh J, Khoury MJ. 1994. Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol. 140(11):1029–1037.
   PubMed Web of Science ®Google Scholar
• Jebabli N, Gaies E, Kharrat M, Njima BB, Klouz A, Chaabouni H, Lakhal M. 2010. N-acetyltransferase 2 (NAT2) in Tunisian population: correlation between acetylation phenotype and genotype. Biol Sci-PJSIR. 53(4):205–211.
   Google Scholar
• Khelil M, Zenati A, Makrelouf M, Otmane A, Tayebi B. 2010. Polymorphisms in NAT2 gene and atherosclerosis in an Algerian population. Arch Med Res. 41(3):215–220.
   PubMed Web of Science ®Google Scholar
• Kim E, Viatour P. 2020. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 52(12):1898–1907.
   PubMed Web of Science ®Google Scholar
• Kimi L, Ghatak S, Yadav RP ,Chhuani L ,Lallawmzuali D ,Pautu JL ,Kumar NS. 2016. Relevance of GSTM1, GSTT1 and GSTP1 gene polymorphism to breast cancer susceptibility in Mizoram population, Northeast India. Biochem Genet. 54(1):41–49.
   PubMed Web of Science ®Google Scholar
• Kocabaş NA, Şardaş S, Cholerton S, Daly AK, Karakaya AE. 2004. N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population. Int J Toxicol. 23(1):25–31.
   PubMed Web of Science ®Google Scholar
• Ladero JM, Martínez C, García-Martín E, Ropero P, Briceño O, Villegas A, Díaz-Rubio M, Agúndez JAG. 2006. Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population. Eur J Cancer. 42(1):73–77.
   PubMed Web of Science ®Google Scholar
• Li CG, Zhao ZM, Hu MG, Liu R. 2012. Predictive role of glutathione-S-transferase gene polymorphisms in risk and prognosis of hepatocellular carcinoma. Asian Pac J Cancer Prev. 13(7):3247–3252.
   PubMedGoogle Scholar
• Li S, Xue F, Zheng Y, Yang P, Lin S, Deng Y, Xu P, Zhou L, Hao Q, Zhai Z. 2019. GSTM1 and GSTT1 null genotype increase the risk of hepatocellular carcinoma: evidence based on 46 studies. Cancer Cell Int. 19(1):1–12.
   PubMed Web of Science ®Google Scholar
• Liu S, An J, Lin J, Liu Y, Bao L, Zhang W, Zhao JJ. 2014. Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma. PloS One. 9(3):e92791.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. 2003. Hepatocellular carcinoma. Lancet. 362(9399):1907–1917.
   PubMed Web of Science ®Google Scholar
• Medjani S, Chellat-Rezgoune D, Kezai T, Chidekh M, Abadi N, Satta, D. 2020. Association of CYP1A1, GSTM1 and GSTT1 gene polymorphisms with risk of prostate cancer in Algerian population. Afr J Urol. 26(1):1–8.
   Web of Science ®Google Scholar
• Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, Katoh T. 2003. Genetic polymorphisms of tobacco-and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol. 129(6):355–360.
   PubMed Web of Science ®Google Scholar
• Reghupaty SC, Mendoza R, Sarkar D. 2019. AEG-1 targeting for inhibiting inflammation: potential anti-HCC strategy. Oncotarget. 10(6):629–630.
   PubMedGoogle Scholar
• Rodrigues-Fleming GH, de Mendonça Fernandes GM, Russo A, Biselli-Chicote PM, Netinho JG, Pavarino ÉC, Goloni-Bertollo EM. 2018. Molecular evaluation of glutathione S transferase family genes in patients with sporadic colorectal cancer. WJG. 24(39):4462–4471.
   PubMed Web of Science ®Google Scholar
• Shek D, Chen D, Read SA, Ahlenstiel G. 2021. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett. 510:48–58.
   PubMed Web of Science ®Google Scholar
• Smith CAD, Smith G, Wolf CR. 1994. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer. 30(13):1921–1935.
   Web of Science ®Google Scholar
• Staretz ME, Murphy SE, Patten CJ, Nunes MG, Koehl W, Amin S, Koenig LA, Guengerich FP, Hecht, SS. 1997. Comparative metabolism of the tobacco-related carcinogens benzo [a] pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, andN′-nitrosonornicotine in human hepatic microsomes. Drug Metabol Dispos. 25(2):154–162.
   PubMed Web of Science ®Google Scholar
• Torkaman‐Boutorabi A, Hoormand M, Naghdi N, Bakhshayesh M, Milanian I. 2007. Genotype and allele frequencies of N‐acetyltransferase 2 and glutathione S‐transferase in the Iranian population. Clin Exp Pharmacol Physiol. 34(11):1207–1211.
   PubMed Web of Science ®Google Scholar
• Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, Zhang D, Zhou W. 2010. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 53(3):508–518.
   PubMed Web of Science ®Google Scholar
• Wang LY, Chen CJ, Zhang YJ, Tsai WY, Lee PH, Feitelson MA, Lee CS, Santella RM. 1998. 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol. 147(3):315–323.
   PubMed Web of Science ®Google Scholar
• Wild CP, Hall AJ. 2000. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res Rev Mutat Res. 462(2–3):381–393.
   PubMed Web of Science ®Google Scholar
• Yu M-W, Chiu Y-H, Chiang Y-C, Chen C-H, Lee T-H, Santella RM, Chern H-D, Liaw Y-F, Chen C-J. 1999. Plasma carotenoids, glutathione S-transferase M1 andT1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Am J Epidemiol. 149(7):621–629.
   PubMed Web of Science ®Google Scholar
• Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM, Liaw YF, Chen PJ, Chen CJ. 2000. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut. 47(5):703–709.
   PubMed Web of Science ®Google Scholar
• Zacharakis G, Aleid A, Aldossari KK. 2018. New and old biomarkers of hepatocellular carcinoma. Hepatoma Res. 4:65.
   Google Scholar
• Zhu Z, Zhang J, Jiang W, Zhang X, Li Y, Xu X. 2015. Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis. Onco Targets Ther. 8:3715–3720.
   PubMed Web of Science ®Google Scholar